WALTHAM,
Mass., Oct. 4, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a
commercial stage biopharmaceutical company
developing an innovative pipeline of cancer therapies, today
announced that on October 1, 2024 the
Company granted inducement awards to purchase up to 62,700 shares
of common stock to five new employees under the Company's 2023
Inducement Plan. The stock options will vest over four years, with
25% of the underlying shares vesting on the one-year anniversary of
the vesting commencement date and 1/48th of the underlying shares
vesting monthly thereafter over 36 months, subject to the
employee's continued service relationship with Syndax through the
applicable vesting dates.
About Syndax
Syndax Pharmaceuticals is a commercial stage biopharmaceutical
company developing an innovative pipeline of cancer therapies.
Highlights of the Company's pipeline include revumenib, a highly
selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), a
monoclonal antibody that blocks the colony stimulating factor 1
(CSF-1) receptor. Syndax is working to unlock the full potential of
its pipeline and is conducting several clinical trials across the
continuum of treatment for both revumenib and Niktimvo. For more
information, please visit www.syndax.com/ or follow the Company on
X (formerly Twitter) and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
View original
content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302266863.html
SOURCE Syndax Pharmaceuticals, Inc.